InsiderSignal.AI

InsiderSignal.ai

ALT - Altimmune, Inc.

Insider Purchase by Durso Jerome Benedict (Pres, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Durso Jerome Benedict, serving as Pres, CEO at Altimmune, Inc. (ALT), purchased 20,000 shares at $3.54 per share, for a total transaction value of $70,790.00. Following this transaction, Durso Jerome Benedict now holds 32,500 shares of ALT.

This purchase represents a 160.00% increase in Durso Jerome Benedict's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, March 6, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 9, 2026, 3 days after the trade was made.

Altimmune, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Durso Jerome Benedict

Durso Jerome Benedict

Pres, CEO

Jerome Benedict Durso is a seasoned biopharmaceutical executive who serves as President, Chief Executive Officer, and Chairman of Altimmune, Inc., a biotechnology company headquartered in Gaithersburg, Maryland[[1]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alt/altimmune/management)[[2]](https://stockanalysis.com/stocks/alt/company/). Durso, age 57, was appointed to the CEO position in January 2026 and brings extensive industry experience to the role[[1]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alt/altimmune/management). Prior to his appointment as CEO, he served as an Independent Director at Altimmune and held the position of Chief Operating Officer at Intercept Pharmaceuticals Inc., demonstrating his deep expertise in pharmaceutical operations and corporate leadership[[3]](https://www.gurufocus.com/insider/51657/jerome-benedict-durso)[[4]](https://www.tipranks.com/experts/insiders/jerome-benedict-durso). At Altimmune, Durso oversees a company of 59 employees focused on developing immunotherapeutic products, including HepTcell for hepatitis B treatment and pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH)[[5]](https://mlq.ai/stocks/ALT/). As of early 2026, Durso directly owns approximately 0.01% of Altimmune's shares, with a stake valued at approximately $53,900[[1]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alt/altimmune/management). His appointment to Altimmune's leadership reflects the company's strategic focus on advancing innovative therapeutic candidates through clinical development[[5]](https://mlq.ai/stocks/ALT/).

View full insider profile →

Trade Price

$3.54

Quantity

20,000

Total Value

$70,790.00

Shares Owned

32,500

Trade Date

Friday, March 6, 2026

10 days ago

SEC Filing Date

Monday, March 9, 2026

Filed 3 days after trade

HEALTHCAREBIOTECHNOLOGY

About Altimmune, Inc.

Company Overview

No company information available
View news mentioning ALT

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4627051

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime